Collegium to buy ADHD medicine Azstarys for up to $785M
Source: SeekingAlpha
2026-03-19 08:41:09 ET
More on Collegium Pharmaceutical
- Collegium Pharmaceutical, Inc. (COLL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- Collegium Pharmaceutical, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Collegium Pharmaceutical, Inc. (COLL) Q4 2025 Earnings Call Transcript
- Collegium targets 31% Jornay revenue growth for 2026 while advancing pain portfolio durability
- Collegium Pharmaceutical Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Collegium to buy ADHD medicine Azstarys for up to $785M
Collegium Pharmaceutical Inc.
NASDAQ: COLL
COLL Trading
-6.15% G/L:
$33.015 Last:
207,449 Volume:
$34.38 Open:
COLL Latest News
March 19, 2026 08:00:00 am
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
COLL Stock Data
$1,476,390,634
30,817,541
0.71%
106
N/A
Pharmaceuticals
Healthcare
US
Stoughton
